Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
+0.62%
1,047.10
+6.41
+0.62%
—1,040.691,048.261,057.851,043.30——
SIXC
Communications
SIXC
Communications
SIXC
+1.04%
566.19
+5.83
+1.04%
—560.36560.36568.72560.36——
SIXE
Energy
SIXE
Energy
SIXE
-0.48%
1,311.39
-6.30
-0.48%
—1,317.691,324.291,335.361,309.90——
SIXI
Industrials
SIXI
Industrials
SIXI
-1.36%
1,585.09
-21.82
-1.36%
—1,606.911,611.511,621.751,583.36——
SIXM
Financials
SIXM
Financials
SIXM
+1.23%
597.55
+7.27
+1.23%
—590.28592.25601.18592.25——
SIXR
Staples
SIXR
Staples
SIXR
+0.46%
831.77
+3.79
+0.46%
—827.98828.20835.94826.74——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
+0.77%
198.56
+1.52
+0.77%
—197.04197.04200.54197.04——
SIXT
Technology
SIXT
Technology
SIXT
-1.73%
2,572.81
-45.39
-1.73%
—2,618.202,638.492,649.452,569.91——
SIXU
Utilities
SIXU
Utilities
SIXU
+0.86%
932.59
+7.93
+0.86%
—924.66929.51938.99929.51——
SIXV
Health care
SIXV
Health care
SIXV
+0.44%
1,455.93
+6.34
+0.44%
—1,449.591,453.441,462.731,452.88——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0.15%
2,140.12
+3.23
+0.15%
—2,136.892,149.922,166.642,139.01——
NBIX:NASDAQ
Neurocrine Biosciences Inc
$129.22
+0.70%
(+0.90) 1D
Mar 30, 2:21:09 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for NBIX...
Open
$129.48
High
$130.10
Low
$128.20
Mkt. cap
12.97B
Avg. vol.
1.07M
Volume
282.14K
P/E ratio
27.67
52-wk high
$160.18
52-wk low
$84.23
EPS
$4.67
Beta
0.32
Shares outstanding
100.36M
No. of employees
2K
News stories
From sources across the web
Profile
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia. The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids. Wikipedia
About Neurocrine Biosciences Inc
CEOKevin C. Gorman
Employees2K
Founded1992
HeadquartersSan Diego, California, United States
SectorBiotechnology
Websiteneurocrine.com
Last report
Feb 11, 2026
Fiscal Period
Q4 2025
Normalized EPS / Estimate
1.88/ (2.30 est.)USD
-18.13%miss
Revenue / Estimate
805.50M/ (789.30M est.)USD
+2.05%beat
Fiscal Q4 2025 earnings call
Waiting for the earnings call
At a glanceInsights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
572.60M
687.50M
794.90M
805.50M
Cost of goods sold
272.40M
255.60M
264.00M
275.80M
Cost of revenue
272.40M
255.60M
264.00M
275.80M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
276.50M
286.30M
291.60M
302.50M
Operating expense
276.50M
286.30M
291.60M
302.50M
Total operating expenses
548.90M
541.90M
555.60M
578.30M
Operating income
23.70M
145.60M
239.30M
227.20M
Other non operating income
-
-
-
-
EBT including unusual items
14.70M
159.50M
291.80M
239.40M
EBT excluding unusual items
45.40M
166.20M
261.50M
253.00M
Income tax expense
6.80M
52.00M
82.30M
85.70M
Effective tax rate
46.26%
32.60%
28.20%
35.80%
Other operating expenses
-
-
-
-
Net income
7.90M
107.50M
209.50M
153.70M
Net profit margin
1.38%
15.64%
26.36%
19.08%
Earnings per share
0.70
1.65
2.17
1.88
Interest and investment income
21.70M
20.60M
22.20M
25.80M
Interest expense
-
-
-
-
Net interest expenses
21.70M
20.60M
22.20M
25.80M
Depreciation and amortization charges
-
-
-
-
EBITDA
31.30M
152.90M
247.00M
234.70M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer